PLSE NASDAQ
Pulse Biosciences, Inc.
1W: +10.8%
1M: +2.0%
3M: +48.5%
YTD: +293.3%
1Y: +202.6%
3Y: +1226.5%
5Y: +149.6%
$53.20
+0.54 (+1.03%)
After Hours: $52.79 (-0.41, -0.77%)
Weekly Expected Move ±9.2%
$43
$48
$53
$58
$63
Credit Risk of going bust: lower than 73% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down more than 99.9%), Pulse Biosciences, Inc. would be worth roughly what it owes.
Total debt $6.8M against a stock market value of $3.76B.
Distance to default 8.19 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 82.1%; Altman Z 132.84. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down more than 99.9%), Pulse Biosciences, Inc. would be worth roughly what it owes.
Total debt $6.8M against a stock market value of $3.76B.
Distance to default 8.19 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 82.1%; Altman Z 132.84. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Oppenheimer's top 50 small- and mid-cap Buy list
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3
30 U.S. stocks flashing Strong Buy ratings as earnings roll in
1,446,611 Shares in Pulse Biosciences, Inc $PLSE Purchased by Bank of America Corp DE
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Why Pulse Biosciences Stock Popped Today
(PLSE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Pulse Biosciences (PLSE) Grants Equity Awards to New Hires Amid High Price-to-Sales Valuation - GuruFocus
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock By Investing.com - Investing.com Nigeria
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock - Investing.com
COO pays nearly $50 a share for Pulse Biosciences (NASDAQ: PLSE) - Stock Titan
Deutsche Bank AG Takes Position in Pulse Biosciences, Inc $PLSE
$PLSE stock is up 7% today. Here's what we see in our data. - quiverquant.com
Insider Purchase: Chief Operating Officer of $PLSE Buys 1,036 Shares - quiverquant.com
Pulse Biosciences (NASDAQ: PLSE) links CFO options to value and revenue goals - Stock Titan
Pulse Biosciences stock hits all-time high at 48.92 USD - Investing.com
Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns - Yahoo Finance
Pulse Biosciences (PLSE) Prices A $75 Million Offering, Is The Stock Fully Valued?
Pulse Biosciences (PLSE) Prices A $75 Million Offering, Is The Stock Fully Valued? - Yahoo Finance
Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences, Inc. Q2 2026 Earnings Call Summary
Pulse Biosciences Q2 Earnings Call Highlights
Pulse Biosciences Inc (PLSE) (Q2 2026) Earnings Call Highlights: Accelerated Enrollment and ...
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
Pulse Biosciences’ Aug. 11 Boston fireside chat will be webcast - Stock Titan
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
Pulse Biosciences' Atrial-Fibrillation Study Passes Halfway Mark - Stock Titan
Pulse Biosciences (PLSE) Stock Looks Above Fair Value Today - simplywall.st
This Little-Known Biotech Stock Just Hit a New 5-Year High
Biotech stocks lead healthcare's overbought list as earnings picks up
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
Pulse Biosciences schedules its next financial update for Aug. 6 - Stock Titan
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Did New Analyst Coverage and Insider Buying Just Shift Pulse Biosciences' (PLSE) Investment Narrative?
Did New Analyst Coverage and Insider Buying Just Shift Pulse Biosciences' (PLSE) Investment Narrative? - Yahoo Finance
Pulse Biosciences (PLSE) Initiated with Buy Rating and $32 Targe - GuruFocus
Canaccord initiates Pulse Biosciences stock with buy on ablation tech By Investing.com - Investing.com India
Canaccord Genuity Initiates Pulse Biosciences at Buy With $32 Price Target - marketscreener.com
Pulse Biosciences (PLSE) Valuation Check After Strong Recent Share Price Momentum - simplywall.st
Pulse Biosciences management to speak at Goldman Sachs healthcare conference - Stock Titan
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy - Yahoo Finance
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Director Robert Duggan buys 660K Pulse Biosciences (PLSE) shares - Stock Titan
$PLSE stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
Pulse Biosciences stock (US73242P1030): Q1 2026 net loss widens to $18.6M on early commercialization - AD HOC NEWS
[SCHEDULE 13D/A] PULSE BIOSCIENCES, INC. Amended Major Shareholder Report - Stock Titan
Pulse Biosciences (PLSE) Co-Chairmen Invest $13.3M in Company St - GuruFocus
Pulse Biosciences (PLSE) Stock Soars After Insider Buying - GuruFocus
Pulse Biosciences (PLSE) Stock Surges 17% on Major $13M Insider Purchase - MEXC
Pulse Biosciences (PLSE) Stock Jumps 17% After $13M Insider Buy - MEXC
Pulse Biosciences (PLSE) Co-Chairmen Invest $13.3M in Company St - GuruFocus
Pulse Biosciences (PLSE) Stock Surges 17% on Major $13M Insider Purchase - Blockonomi
Pulse Biosciences (PLSE) Stock Jumps 17% After $13M Insider Buy - CoinCentral
Pulse Biosciences stock jumps after insiders buy $13.3M in shares - Investing.com Nigeria
Pulse Biosciences stock jumps after insiders buy $13.3M in shares - Investing.com
Pulse Biosciences stock jumps after insiders buy $13.3M in shares - Investing.com
Pulse Biosciences Co-Chairmen Purchase $13.3 Million in Company Stock - citybiz
Pulse Biosciences insiders buy $13.3 million in stock By Investing.com - Investing.com Australia
$13.3M insider stock buy: Pulse Biosciences chiefs add 675K shares - Stock Titan
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million - Yahoo Finance
Pulse Biosciences (NASDAQ: PLSE) CEO adds 15,000 shares in open-market buy - Stock Titan
Pulse Biosciences CEO Paul Laviolette buys $295,350 in company stock By Investing.com - Investing.com South Africa
Pulse Biosciences CEO Paul Laviolette buys $295,350 in company stock By Investing.com - Investing.com Nigeria
Pulse Biosciences director Robert Duggan buys $13 million in shares By Investing.com - Investing.com Nigeria
Pulse Biosciences 10% Owner Purchased Shares Worth Over $12M - TradingView
Pulse Biosciences director Robert Duggan buys $13 million in shares - Investing.com
[Form 4] PULSE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan
Robert Duggan adds 660K Pulse Biosciences (PLSE) shares in open-market buy - Stock Titan
Major holder controls 71.6% as Pulse Biosciences (NASDAQ: PLSE) outlines 2026 vote - Stock Titan
PLUS Stock Price, Quote & Chart | EPLUS INC (NASDAQ:PLUS) - ChartMill
Is Pulse Biosciences (PLSE) Quietly Redefining Its Core Identity Around Atrial Fibrillation?
Pulse Biosciences Q1 Earnings Call Highlights
PLSE Q1 2026 Earnings Transcript
PLSE Q1 2026 Earnings Transcript
Pulse Biosciences to webcast May 13 presentation from BofA conference - Stock Titan
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo! Finance Canada
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Turbett Surgical Appoints Kevin Danahy as President and Chief Executive Officer to Lead Growth Phase
Major holder in Pulse Biosciences (PLSE) eyes buys under $59.98M ATM - Stock Titan
Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript
PLSE Q4 2025 Earnings Transcript
PLSE Q4 2025 Earnings Transcript
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Earnings Scheduled For May 4, 2026